Meeting
2022 ASCO Annual Meeting
Molecular characterization and subsequent treatments after encorafenib-cetuximab +/- binimetinib in BRAF V600E-mutated colorectal cancer.
Authors
Javier Ros Montañá
Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology, Vall d’Hebron University Hospital (HUVH), Barcelona, Spain
Javier Ros Montañá , Victor Navarro , Raquel Comas , Ariadna Garcia , Nadia Saoudi Gonzalez , Iosune Baraibar , Francesc Salva , Ana Vivancos , Josep Tabernero , Elena Elez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3562)
DOI
10.1200/JCO.2022.40.16_suppl.3562
Abstract #
3562
Poster Bd #
356
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Impact of cholangiocarcinoma (CC) molecular heterogeneity on outcome during first-line chemotherapy and access to targeted therapies in early clinical trials (CT).
First Author: Helena Verdaguer
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world analyses of BRAF alterations in patients with non-colorectal gastrointestinal cancers.
First Author: Amit Mahipal
Poster
2022 ASCO Annual Meeting
Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development.
First Author: Dazhi Liu
Poster
2019 Gastrointestinal Cancers Symposium
Molecular comparison of primary colorectal cancer (pCRC) with peritoneal metastases (PM).
First Author: Matthew K Stein